Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Total Liabilities (2019 - 2026)

Enliven Therapeutics has reported Total Liabilities over the past 8 years, most recently at $11.5 million for Q1 2026.

  • Quarterly results put Total Liabilities at $11.5 million for Q1 2026, down 19.53% from a year ago — trailing twelve months through Mar 2026 was $11.5 million (down 19.53% YoY), and the annual figure for FY2025 was $16.6 million, up 4.1%.
  • Total Liabilities reached $11.5 million in Q1 2026 per ELVN's latest filing, down from $16.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $26.0 million in Q4 2023 and bottomed at $1.8 million in Q3 2022.
  • Median Total Liabilities over the past 5 years was $14.3 million (2025), compared with a mean of $13.9 million.
  • The largest annual shift saw Total Liabilities tumbled 76.25% in 2022 before it soared 576.18% in 2023.
  • Over 5 years, Total Liabilities stood at $10.4 million in 2022, then skyrocketed by 150.25% to $26.0 million in 2023, then plummeted by 38.7% to $15.9 million in 2024, then increased by 4.1% to $16.6 million in 2025, then plummeted by 30.67% to $11.5 million in 2026.
  • Business Quant data shows Total Liabilities for ELVN at $11.5 million in Q1 2026, $16.6 million in Q4 2025, and $14.8 million in Q3 2025.